| Relief of overall digestive symptoms — YIT 10347 | In the per-protocol analysis, the overall score decreased in 35 of 39 participants receiving YIT 10347 and 28 of 40 controls. The distribution across three categories (improved, unchanged, worsened) differed between groups (p=0.016). | 2/4 LowPrecision of the estimate: Small sample or uncertainty about the size of the effect. Consistency across studies: Inconsistency has not been established for this specific strain, form, and outcome. The original assessment applied no additional downgrade for this reason (0 levels). Applicability to the specified group: The conclusion is limited to this strain, the participants, the outcome measured, and the comparator. Possible publication bias: There are too few studies to assess publication bias reliably. There is no direct evidence of missing studies. The original assessment applied no additional downgrade for this reason (0 levels). Risk of bias: Missing outcome data, group allocation, or selection of analyses pose limitations. Details appear below. | 11 publication describedBifidobacterium bifidum YIT 10347 fermented milk exerts beneficial effects on gastrointestinal discomfort and symptoms in healthy adults: A double-blind, randomized, placebo-controlled study ↗ | 100 Japanese adults with transient digestive symptoms. The per-protocol analysis included 39 and 40 participants in the two groups. | - Bifidobacterium bifidum YIT 10347 fermented milk exerts beneficial effects on gastrointestinal discomfort and symptoms in healthy adults: A double-blind, randomized, placebo-controlled study ↗
|
|---|
| Mean overall digestive symptom score — YIT 10347 | The mean Gastrointestinal Symptom Rating Scale (GSRS) score changed by −0.67 versus −0.46 points (p=0.361). No statistically significant difference was shown. | 2/4 LowPrecision of the estimate: Small sample or uncertainty about the size of the effect. Consistency across studies: Inconsistency has not been established for this specific strain, form, and outcome. The original assessment applied no additional downgrade for this reason (0 levels). Applicability to the specified group: The conclusion is limited to this strain, the participants, the outcome measured, and the comparator. Possible publication bias: There are too few studies to assess publication bias reliably. There is no direct evidence of missing studies. The original assessment applied no additional downgrade for this reason (0 levels). Risk of bias: Missing outcome data, group allocation, or selection of analyses pose limitations. Details appear below. | 11 publication describedBifidobacterium bifidum YIT 10347 fermented milk exerts beneficial effects on gastrointestinal discomfort and symptoms in healthy adults: A double-blind, randomized, placebo-controlled study ↗ | 100 Japanese adults with transient digestive symptoms. The per-protocol analysis included 39 and 40 participants in the two groups. | - Bifidobacterium bifidum YIT 10347 fermented milk exerts beneficial effects on gastrointestinal discomfort and symptoms in healthy adults: A double-blind, randomized, placebo-controlled study ↗
|
|---|
| Bloating — YIT 10347 | Mean bloating scores decreased by 0.62 and 0.70 points, respectively. No significant difference was found between groups (p=0.984). | 2/4 LowPrecision of the estimate: Outcome data are sparse or incomplete, or the confidence interval was not reported. Consistency across studies: One study directly assessed the specific form and strain. Inconsistency across studies cannot be assessed. The original assessment applied no additional downgrade for this reason (0 levels). Applicability to the specified group: The stated scope is this specific fermented milk product and the outcome measured. The risk-of-bias section accounts for the outcome's secondary status and participant attrition. Possible publication bias: There are too few studies of this specific strain to assess publication bias reliably. The original assessment applied no additional downgrade for this reason (0 levels). Risk of bias: Substantial attrition and a narrow comparison involving a specific product limit interpretation. | 11 publication describedBifidobacterium bifidum YIT 10347 fermented milk exerts beneficial effects on gastrointestinal discomfort and symptoms in healthy adults: A double-blind, randomized, placebo-controlled study ↗ | 100 Japanese adults with transient digestive symptoms. The per-protocol analysis included 39 and 40 participants in the two groups. | - Bifidobacterium bifidum YIT 10347 fermented milk exerts beneficial effects on gastrointestinal discomfort and symptoms in healthy adults: A double-blind, randomized, placebo-controlled study ↗
|
|---|
| Overall IBS symptom relief — live MIMBb75 | By the end of 4 weeks, 43% of participants receiving live MIMBb75 and 8% receiving placebo reported adequate relief. At 2 weeks after treatment ended, the figures were 47% and 11%, respectively. | 2/4 LowPrecision of the estimate: Small sample or uncertainty about the size of the effect. Consistency across studies: Inconsistency has not been established for this specific strain, form, and outcome. The original assessment applied no additional downgrade for this reason (0 levels). Applicability to the specified group: The conclusion is limited to this strain, the participants, the outcome measured, and the comparator. Possible publication bias: There are too few studies to assess publication bias reliably. There is no direct evidence of missing studies. The original assessment applied no additional downgrade for this reason (0 levels). Risk of bias: Missing outcome data, group allocation, or selection of analyses pose limitations. Details appear below. | 11 publication describedRandomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study ↗ | 122 adults with IBS: 60 in the strain group and 62 in the placebo group | - Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study ↗
|
|---|
| Pain reduction with overall IBS symptom relief — HI-MIMBb75 | Among participants receiving HI-MIMBb75, 74 of 221 met both criteria in at least 4 of the 8 weeks, as did 43 of 222 receiving placebo. The criteria were a reduction of at least 30% in abdominal pain and adequate relief of overall symptoms. The relative likelihood of this response was 1.7 (95% confidence interval 1.3–2.4). | 2/4 LowPrecision of the estimate: Small sample or uncertainty about the size of the effect. Consistency across studies: Inconsistency has not been established for this specific strain, form, and outcome. The original assessment applied no additional downgrade for this reason (0 levels). Applicability to the specified group: The conclusion is limited to this strain, the participants, the outcome measured, and the comparator. Possible publication bias: There are too few studies to assess publication bias reliably. There is no direct evidence of missing studies. The original assessment applied no additional downgrade for this reason (0 levels). Risk of bias: Missing outcome data, group allocation, or selection of analyses pose limitations. Details appear below. | 11 publication describedHeat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial ↗ | 443 adults with IBS: 221 in the strain group and 222 in the placebo group | - Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial ↗
|
|---|
| Quality of life with constipation — G9-1 | The overall constipation-related quality-of-life score changed by −0.65 versus −0.54 points. No significant advantage over the comparator was found. | 2/4 LowPrecision of the estimate: Small sample or uncertainty about the size of the effect. Consistency across studies: Inconsistency has not been established for this specific strain, form, and outcome. The original assessment applied no additional downgrade for this reason (0 levels). Applicability to the specified group: The conclusion is limited to this strain, the participants, the outcome measured, and the comparator. Possible publication bias: There are too few studies to assess publication bias reliably. There is no direct evidence of missing studies. The original assessment applied no additional downgrade for this reason (0 levels). Risk of bias: Missing outcome data, group allocation, or selection of analyses pose limitations. Details appear below. | 11 publication describedBifidobacterium bifidum G9-1 and Quality of Life in Chronic Constipation: A Multicenter, Double-Blind, Randomized Controlled Trial ↗ | 150 adults with constipation were randomized, and 140 were included in the analysis. Participants could continue stable usual care. | - Bifidobacterium bifidum G9-1 and Quality of Life in Chronic Constipation: A Multicenter, Double-Blind, Randomized Controlled Trial ↗
|
|---|
| Stool outcomes in chronic constipation — CCFM16 | One study reported improved stool consistency and a higher proportion of stool responders, but overall symptoms and quality of life did not differ significantly. | 2/4 LowPrecision of the estimate: Outcome data are sparse or incomplete, or the confidence interval was not reported. Consistency across studies: One study directly assessed the specific form and strain. Inconsistency across studies cannot be assessed. The original assessment applied no additional downgrade for this reason (0 levels). Applicability to the specified group: Direct evidence for the specified participants, strain, form, and outcome. Possible publication bias: There are too few studies of this specific strain to assess publication bias reliably. The original assessment applied no additional downgrade for this reason (0 levels). Risk of bias: This was a small study of a subjective outcome. Details on the analysis or group allocation were incomplete, and multiple comparisons were made. | 11 publication describedA randomised, double-blind, placebo-controlled trial of Bifidobacterium bifidum CCFM16 for manipulation of the gut microbiota and relief from chronic constipation ↗ | 103 adults with chronic constipation | - A randomised, double-blind, placebo-controlled trial of Bifidobacterium bifidum CCFM16 for manipulation of the gut microbiota and relief from chronic constipation ↗
|
|---|
| Lactose tolerance after one month of use — 900791 | After one month of use, no benefit over the control was found. Only 29 of 45 participants completed the final test, making the estimate imprecise. | 1/4 Very lowPrecision of the estimate: Outcome data are sparse or incomplete, or the confidence interval was not reported. Consistency across studies: One study directly assessed the specific form and strain. Inconsistency across studies cannot be assessed. The original assessment applied no additional downgrade for this reason (0 levels). Applicability to the specified group: Direct evidence for the specified adults with lactose intolerance and this product. The risk-of-bias section accounts for attrition and the lack of dietary control. Possible publication bias: There are too few studies of this specific strain to assess publication bias reliably. The original assessment applied no additional downgrade for this reason (0 levels). Risk of bias: The final test was missing for one third of participants. Blinding and the order of interventions were unclear. The result depends on the specific food used as the carrier. | 11 publication describedImprovement in Lactose Tolerance in Hypolactasic Subjects Consuming Ice Creams with High or Low Concentrations of Bifidobacterium bifidum 900791 ↗ | 45 adults with a positive hydrogen breath test and symptoms were randomized. Of these, 29 completed the final test. | - Improvement in Lactose Tolerance in Hypolactasic Subjects Consuming Ice Creams with High or Low Concentrations of Bifidobacterium bifidum 900791 ↗
|
|---|
| Days with low severity of cold-like symptoms — R0071 | Students receiving R0071 recorded a higher proportion of days with a total score of 6 or less across nine symptoms. A total score above 6 was recorded on 118 observation days with R0071 and 222 days with placebo. | 2/4 LowPrecision of the estimate: Small sample or uncertainty about the size of the effect. Consistency across studies: Inconsistency has not been established for this specific strain, form, and outcome. The original assessment applied no additional downgrade for this reason (0 levels). Applicability to the specified group: The conclusion is limited to this strain, the participants, the outcome measured, and the comparator. Possible publication bias: There are too few studies to assess publication bias reliably. There is no direct evidence of missing studies. The original assessment applied no additional downgrade for this reason (0 levels). Risk of bias: Missing outcome data, group allocation, or selection of analyses pose limitations. Details appear below. | 11 publication describedBifidobacterium bifidum R0071 results in a greater proportion of healthy days and a lower percentage of academically stressed students reporting a day of cold/flu: a randomised, double-blind, placebo-controlled study ↗ | In a setting of academic stress, 583 students were randomized to four groups, and 581 were included in the analysis. | - Bifidobacterium bifidum R0071 results in a greater proportion of healthy days and a lower percentage of academically stressed students reporting a day of cold/flu: a randomised, double-blind, placebo-controlled study ↗
|
|---|
| Mental well-being and quality of life — YIT 10347 | Secondary measures of mental well-being and quality of life did not differ significantly between groups. This was not a standalone trial of sleep disorders. | 2/4 LowPrecision of the estimate: Outcome data are sparse or incomplete, or the confidence interval was not reported. Consistency across studies: One study directly assessed the specific form and strain. Inconsistency across studies cannot be assessed. The original assessment applied no additional downgrade for this reason (0 levels). Applicability to the specified group: The stated scope is this specific fermented milk product and the outcome measured. The risk-of-bias section accounts for the outcome's secondary status and participant attrition. Possible publication bias: There are too few studies of this specific strain to assess publication bias reliably. The original assessment applied no additional downgrade for this reason (0 levels). Risk of bias: Substantial attrition and a narrow comparison involving a specific product limit interpretation. | 11 publication describedBifidobacterium bifidum YIT 10347 fermented milk exerts beneficial effects on gastrointestinal discomfort and symptoms in healthy adults: A double-blind, randomized, placebo-controlled study ↗ | 100 adults with transient digestive symptoms, with 79 included in the per-protocol analysis | - Bifidobacterium bifidum YIT 10347 fermented milk exerts beneficial effects on gastrointestinal discomfort and symptoms in healthy adults: A double-blind, randomized, placebo-controlled study ↗
|
|---|